MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT ID: NCT04630808
Last Updated: 2025-09-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
696 participants
INTERVENTIONAL
2020-11-09
2025-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT04445519
Phase 2 Dose-Response Study Evaluating the Safety and Efficacy of NCX 470 vs Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension
NCT03657797
Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma
NCT00441883
A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension
NCT00788541
Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients
NCT00069706
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NCX 470 0.1%
NCX 470 Ophthalmic Solution, 0.1% dosed once daily to both eyes
NCX 470 0.1%
NCX 470 Ophthalmic Solution, 0.1%
Latanoprost 0.005%
Latanoprost Ophthalmic Solution, 0.005% dosed once daily to both eyes
Latanoprost 0.005%
Latanoprost Ophthalmic Solution, 0.005%
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NCX 470 0.1%
NCX 470 Ophthalmic Solution, 0.1%
Latanoprost 0.005%
Latanoprost Ophthalmic Solution, 0.005%
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Qualifying IOP at 3 time points through the day at 2 visits following washout of IOP-lowering medication, if applicable
* Qualifying best-corrected visual acuity in each eye
* Ability to provide informed consent and follow study instructions
Exclusion Criteria
* Clinically significant ocular disease in either eye
* Previous complicated surgery or certain types of glaucoma surgery in either eye
* Incisional ocular surgery or severe trauma in either eye within the past 6 months
* Uncontrolled systemic disease
18 Years
84 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nicox Ophthalmics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nicox Ophthalmics
Role: STUDY_DIRECTOR
Nicox Ophthalmics, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nicox Clinical Site
Dothan, Alabama, United States
Nicox Clinical Site
Chandler, Arizona, United States
Nicox Clinical Site
Phoenix, Arizona, United States
Nicox Clinical Site
Burbank, California, United States
Nicox Clinical Site
Garden Grove, California, United States
Nicox Clinical Site
Huntington Beach, California, United States
Nicox Clinical Site
La Jolla, California, United States
Nicox Clinical Site
Murrieta, California, United States
Nicox Clinical Site
Newport Beach, California, United States
Nicox Clinical Site
Pasadena, California, United States
Nicox Clinical Site
Petaluma, California, United States
Nicox Clinical Site
Redlands, California, United States
Nicox Clinical Site
San Francisco, California, United States
Nicox Clinical Site
Danbury, Connecticut, United States
Nicox Clinical Site
Boynton Beach, Florida, United States
Nicox Clinical Site
Delray Beach, Florida, United States
Nicox Clinical Site
Fort Lauderdale, Florida, United States
Nicox Clinical Site
Fort Myers, Florida, United States
Nicox Clinical Site
Jacksonville, Florida, United States
Nicox Clinical Site
Jupiter, Florida, United States
Nicox Clinical Site
Lakeland, Florida, United States
Nicox Clinical Site
Largo, Florida, United States
Nicox Clinical Site
Mt. Dora, Florida, United States
Nicox Clinical Site
Venice, Florida, United States
Nicox Clinical Site
Morrow, Georgia, United States
Nicox Clinical Site
Roswell, Georgia, United States
Nicox Clinical Site
Peoria, Illinois, United States
Nicox Clinical Site
Rock Island, Illinois, United States
Nicox Clinical Site
Indianapolis, Indiana, United States
Nicox Clinical Site
Bangor, Maine, United States
Nicox Clinical Site
Boston, Massachusetts, United States
Nicox Clinical Site
Lancaster, Massachusetts, United States
Nicox Clinical Site
Grand Rapids, Michigan, United States
Nicox Clinical Site
Chaska, Minnesota, United States
Nicox Clinical Site
Kansas City, Missouri, United States
Nicox Clinical Site
St Louis, Missouri, United States
Nicox Clinical Site
Clifton Park, New York, United States
Nicox Clinical Site
The Bronx, New York, United States
Nicox Clinical Site
Troy, New York, United States
Nicox Clinical Site
Asheville, North Carolina, United States
Nicox Clinical Site
Winston-Salem, North Carolina, United States
Nicox Clinical Site
Fargo, North Dakota, United States
Nicox Clinical Site
Cincinnati, Ohio, United States
Nicox Clinical Site
Cincinnati, Ohio, United States
Nicox Clinical Site
Eugene, Oregon, United States
Nicox Clinical Site
Cranberry Township, Pennsylvania, United States
Nicox Clinical Site
Kingston, Pennsylvania, United States
Nicox Clinical Site
Memphis, Tennessee, United States
Nicox Clinical Site
Memphis, Tennessee, United States
Nicox Clinical Site
Austin, Texas, United States
Nicox Clinical Site
El Paso, Texas, United States
Nicox Clinical Site
Houston, Texas, United States
Nicox Clinical Site
Houston, Texas, United States
Nicox Clinical Site
Mission, Texas, United States
Nicox Clinical Site
San Antonio, Texas, United States
Nicox Clinical Site
San Antonio, Texas, United States
Nicox Clinical Site
San Antonio, Texas, United States
Nicox Clinical Site
Sugar Land, Texas, United States
Nicox Clinical Site
St. George, Utah, United States
Nicox Clinical Site
Falls Church, Virginia, United States
Nicox Clinical Site
Bellevue, Washington, United States
Nicox Clinical Site
Seattle, Washington, United States
Nicox Clinical Site
Seattle, Washington, United States
Nicox Clinical Site
Lanzhou, Gansu, China
Nicox Clinical Site
Shantou, Guangdong, China
Nicox Clinical Site
Harbin, Heilongjiang, China
Nicox Clinical Site
Zhengzhou, Henan, China
Nicox Clinical Site
Zhengzhou, Henan, China
Nicox Clinical Site
Wuhan, Hubei, China
Nicox Clinical Site
Yichang, Hubei, China
Nicox Clinical Site
Changsha, Hunan, China
Nicox Clinical Site
Changsha, Huna, China
Nicox Clinical Site
Nanchang, Jiangxi, China
Nicox Clinical Site
Changchun, Jilin, China
Nicox Clinical Site
Dalian, Liaoning, China
Nicox Clinical Site
Xi'an, Shaanxi, China
Nicox Clinical Site
Jinan, Shandong, China
Nicox Clinical Site
Qingdao, Shandong, China
Nicox Clinical Site
Chengdu, Sichuan, China
Nicox Clinical Site
Wenzhou, Xhejiang, China
Nicox Clinical Site
Beijing, , China
Nicox Clinical Site
Beijing, , China
Nicox Clinical Site
Chongqing, , China
Nicox Clinical Site
Shanghai, , China
Nicox Clinical Site
Shanghai, , China
Nicox Clinical Site
Shanghai, , China
Nicox Clinical Site
Tianjing, , China
Nicox Clinical Site
Tianjing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCX-470-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.